Additional information
| Active substance | Cefdinir |
|---|---|
| Storage conditions | Store at 20-25В°C (68-77В°F) |
| Side effects | Bleeding, bruising, gastrointestinal discomfort, thrombotic thrombocytopenic purpura |
| Effects | Reduces the risk of stroke, myocardial infarction, and vascular death in patients with atherosclerosis |
| Dosage (sports) | Not applicable |
| Dosage (medical) | 75 mg once daily |
| Half-life | Approximately 6 hours |
| Main action | Inhibits platelet aggregation |
| Substance class | Thienopyridine antiplatelet agent |
| Formula | C16H16ClNO2SВ·H2SO4 |
| Chemical name | Methyl (+)-(S)-О±-(2-chlorophenyl)-6,7-dihydrothieno[3,2-c]pyridine-5(4H)-acetate sulfate (1:1) |
| Trade name | Plavix |
| Blood pressure | No direct effect |
| WAREHOUSE | International Warehouse 2 |
| Also known as | Plavix, Iscover |
| Lab Test | Monitoring not typically required, but platelet function tests can be affected |
| Aromatization | No |
| Hepatotoxicity | Low |
| HBR | No |
| Water Retention | No |
| Acne | No |
| Classification | Antibiotic Cephalosporin (Third Generation) |
| Use in sports | Not typically used in sports |
| Manufacturer | Generica |
Reviews
There are no reviews yet.